Trials / Not Yet Recruiting
Not Yet RecruitingNCT07141186
QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy
A Prospective, Single-Arm, Phase II Trial of QL1706 in Patients With Recurrent and/or Metastatic Cervical Cancer Who Had Developed Resistance to Prior PD-1/PD-L1 Antibody Therapy
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To explore the efficacy and safety of administrating QL1706 in patients with recurrent and/or metastatic cervical cancer who had developed resistance to prior PD-1/PD-L1 antibody therapies.
Detailed description
The application of PD-1/PD-L1 antibodies in cervical cancer is becoming increasingly widespread. However, monotherapy with PD-1 inhibitors demonstrates only a 10-20% response rate and a median progression-free survival of merely 2 months in patients with recurrent or metastatic cervical cancer. To address the issue of resistance to PD-1/PD-L1 antibodies in cervical cancer patients, we plan to conduct a clinical study. This study will administer a PD-1/CTLA-4 bispecific antibody to patients with recurrent or metastatic cervical cancer who are resistant to PD-1/PD-L1 therapy, thereby evaluating the efficacy and safety profile of the bispecific antibody in this specific patient population.
Conditions
- Cervical Cancer
- Cervical Cancer Metastatic
- Cervical Cancer Recurrent
- Cervical Adenocarcinoma
- Cervical Cancer Squamous Cell
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QL1706 (bispecific antibody targeting PD-1 and CLTA-4) | Enrolled patients will receive intravenous infusion of QL1706 once every 3 weeks at a dose of 5.0 mg/kg until disease progression, death, intolerable treatment toxicity, or withdrawal from the clinical trial for any reason. |
Timeline
- Start date
- 2025-10-01
- Primary completion
- 2027-10-01
- Completion
- 2030-10-01
- First posted
- 2025-08-26
- Last updated
- 2025-08-26
Source: ClinicalTrials.gov record NCT07141186. Inclusion in this directory is not an endorsement.